<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33155358</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-4833</ISSN><JournalIssue CitedMedium="Internet"><Volume>185</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>American journal of medical genetics. Part A</Title><ISOAbbreviation>Am J Med Genet A</ISOAbbreviation></Journal><ArticleTitle>Genotype-phenotype correlation in seven motor neuron disease families with novel ALS2 mutations.</ArticleTitle><Pagination><StartPage>344</StartPage><EndPage>354</EndPage><MedlinePgn>344-354</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ajmg.a.61951</ELocationID><Abstract><AbstractText>Autosomal-recessive mutations in the Alsin Rho guanine nucleotide exchange factor (ALS2) gene may cause specific subtypes of childhood-onset progressive neurodegenerative motor neuron diseases (MND). These diseases can manifest with a clinical continuum from infantile ascending hereditary spastic paraplegia (IAHSP) to juvenile-onset forms with or without lower motor neuron involvement, the juvenile primary lateral sclerosis (JPLS) and the juvenile amyotrophic lateral sclerosis (JALS). We report 11 patients from seven unrelated Turkish and Yemeni families with clinical signs of IAHSP or JPLS. We performed haplotype analysis or next-generation panel sequencing followed by Sanger Sequencing to unravel the genetic disease cause. We described their clinical phenotype and analyzed the pathogenicity of the detected variants with bioinformatics tools. We further reviewed all previously reported cases with ALS2-related MND. We identified five novel homozygous pathogenic variants in ALS2 at various positions: c.275_276delAT (p.Tyr92CysfsTer11), c.1044C&gt;G (p.Tyr348Ter), c.1718C&gt;A (p.Ala573Glu), c.3161T&gt;C (p.Leu1054Pro), and c.1471+1G&gt;A (NM_020919.3, NP_065970.2). In our cohort, disease onset was in infancy or early childhood with rapid onset of motor neuron signs. Muscle weakness, spasticity, severe dysarthria, dysphagia, and facial weakness were common features in the first decade of life. Frameshift and nonsense mutations clustered in the N-terminal Alsin domains are most prevalent. We enriched the mutational spectrum of ALS2-related disorders with five novel pathogenic variants. Our study indicates a high detection rate of ALS2 mutations in patients with a clinically well-characterized early onset MND. Intrafamilial and even interfamilial diversity in patients with identical pathogenic variants suggest yet unknown modifiers for phenotypic expression.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. American Journal of Medical Genetics Part A published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sprute</LastName><ForeName>Rosanne</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-2457-6437</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine and the Faculty of Mathematics and Natural Sciences, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and University Hospital Cologne, Department of Pediatrics, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jergas</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and the Faculty of Mathematics and Natural Sciences, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and University Hospital Cologne, Department of Pediatrics, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and University Hospital Cologne, Department of Neurology, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#xd6;lmez</LastName><ForeName>Akg&#xfc;n</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatric Neurology, Hacettepe University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alawbathani</LastName><ForeName>Salem</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Cologne Center for Genomics, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karasoy</LastName><ForeName>Hatice</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ege University School of Medicine, Izmir, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dafsari</LastName><ForeName>Hormos Salimi</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and the Faculty of Mathematics and Natural Sciences, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and University Hospital Cologne, Department of Pediatrics, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>Kerstin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and the Faculty of Mathematics and Natural Sciences, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and University Hospital Cologne, Department of Pediatrics, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daimag&#xfc;ler</LastName><ForeName>H&#xfc;lya-Sevcan</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and the Faculty of Mathematics and Natural Sciences, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and University Hospital Cologne, Department of Pediatrics, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>N&#xfc;rnberg</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and the Faculty of Mathematics and Natural Sciences, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cologne Center for Genomics, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muntoni</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>The Dubowitz Neuromuscular Centre, National Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre, UCL Great Ormond Street Institute of Child Health, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Topaloglu</LastName><ForeName>Haluk</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pediatric Neurology, Hacettepe University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uyanik</LastName><ForeName>G&#xf6;khan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Medical School, Sigmund Freud Private University, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Medical Genetics, Hanusch Hospital, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cirak</LastName><ForeName>Sebahattin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and the Faculty of Mathematics and Natural Sciences, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and University Hospital Cologne, Department of Pediatrics, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Med Genet A</MedlineTA><NlmUniqueID>101235741</NlmUniqueID><ISSNLinking>1552-4825</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C438187">ALS2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018389">Codon, Nonsense</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020662">Guanine Nucleotide Exchange Factors</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C536416">Primary lateral sclerosis juvenile</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018389" MajorTopicYN="N">Codon, Nonsense</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016368" MajorTopicYN="N">Frameshift Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020662" MajorTopicYN="N">Guanine Nucleotide Exchange Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="N">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015419" MajorTopicYN="N">Spastic Paraplegia, Hereditary</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">familial ALS</Keyword><Keyword MajorTopicYN="N">infantile ascending hereditary spastic paraplegia (IAHSP)</Keyword><Keyword MajorTopicYN="N">juvenile amyotrophic lateral sclerosis (JALS)</Keyword><Keyword MajorTopicYN="N">linkage analysis</Keyword><Keyword MajorTopicYN="N">whole-exome sequencing</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33155358</ArticleId><ArticleId IdType="doi">10.1002/ajmg.a.61951</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Bede, P., Elamin, M., Byrne, S., McLaughlin, R. L., Kenna, K., Vajda, A., &#x2026; Hardiman, O. (2013). Basal ganglia involvement in amyotrophic lateral sclerosis. Neurology, 81(24), 2107-2115. https://doi.org/10.1212/01.wnl.0000437313.80913.2c</Citation></Reference><Reference><Citation>Daud, S., Kakar, N., Goebel, I., Hashmi, A., Yaqub, T., Nurnberg, G., &#x2026; Borck, G. (2016). Identification of two novel ALS2 mutations in infantile-onset ascending hereditary spastic paraplegia. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 17(3-4), 260-265. https://doi.org/10.3109/21678421.2015.1125501</Citation></Reference><Reference><Citation>Devon, R. S., Helm, J. R., Rouleau, G. A., Leitner, Y., Lerman-Sagie, T., Lev, D., &amp; Hayden, M. R. (2003). The first nonsense mutation in alsin results in a homogeneous phenotype of infantile-onset ascending spastic paralysis with bulbar involvement in two siblings. Clinical Genetics, 64(3), 210-215.</Citation></Reference><Reference><Citation>Devon, R. S., Orban, P. C., Gerrow, K., Barbieri, M. A., Schwab, C., Cao, L. P., &#x2026; Hayden, M. R. (2006). Als2-deficient mice exhibit disturbances in endosome trafficking associated with motor behavioral abnormalities. Proceedings of the National Academy of Sciences of the United States of America, 103(25), 9595-9600. https://doi.org/10.1073/pnas.0510197103</Citation></Reference><Reference><Citation>Edgar, R. C. (2004). MUSCLE: Multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Research, 32(5), 1792-1797. https://doi.org/10.1093/nar/gkh340</Citation></Reference><Reference><Citation>Eker, H. K., Unlu, S. E., Al-Salmi, F., &amp; Crosby, A. H. (2014). A novel homozygous mutation in ALS2 gene in four siblings with infantile-onset ascending hereditary spastic paralysis. European Journal of Medical Genetics, 57(6), 275-278. https://doi.org/10.1016/j.ejmg.2014.03.006</Citation></Reference><Reference><Citation>Eymard-Pierre, E., Lesca, G., Dollet, S., Santorelli, F. M., di Capua, M., Bertini, E., &amp; Boespflug-Tanguy, O. (2002). Infantile-onset ascending hereditary spastic paralysis is associated with mutations in the alsin gene. American Journal of Human Genetics, 71(3), 518-527. https://doi.org/10.1086/342359</Citation></Reference><Reference><Citation>Eymard-Pierre, E., Yamanaka, K., Haeussler, M., Kress, W., Gauthier-Barichard, F., Combes, P., &#x2026; Boespflug-Tanguy, O. (2006). Novel missense mutation in ALS2 gene results in infantile ascending hereditary spastic paralysis. Annals of Neurology, 59(6), 976-980. https://doi.org/10.1002/ana.20879</Citation></Reference><Reference><Citation>Flor-de-Lima, F., Sampaio, M., Nahavandi, N., Fernandes, S., &amp; Leao, M. (2014). Alsin related disorders: Literature review and case study with novel mutations. Case Reports in Genetics, 2014, 691515-691515. https://doi.org/10.1155/2014/691515</Citation></Reference><Reference><Citation>Gautam, M., Jara, J. H., Sekerkova, G., Yasvoina, M. V., Martina, M., &amp; Ozdinler, P. H. (2016). Absence of alsin function leads to corticospinal motor neuron vulnerability via novel disease mechanisms. Human Molecular Genetics, 25(6), 1074-1087. https://doi.org/10.1093/hmg/ddv631</Citation></Reference><Reference><Citation>Gros-Louis, F., Meijer, I. A., Hand, C. K., Dube, M. P., MacGregor, D. L., Seni, M. H., &#x2026; Rouleau, G. A. (2003). An ALS2 gene mutation causes hereditary spastic paraplegia in a Pakistani kindred. Annals of Neurology, 53(1), 144-145. https://doi.org/10.1002/ana.10422</Citation></Reference><Reference><Citation>Hadano, S., Benn, S. C., Kakuta, S., Otomo, A., Sudo, K., Kunita, R., &#x2026; Ikeda, J. E. (2006). Mice deficient in the Rab5 guanine nucleotide exchange factor ALS2/alsin exhibit age-dependent neurological deficits and altered endosome trafficking. Human Molecular Genetics, 15(2), 233-250. https://doi.org/10.1093/hmg/ddi440</Citation></Reference><Reference><Citation>Hadano, S., Hand, C. K., Osuga, H., Yanagisawa, Y., Otomo, A., Devon, R. S., &#x2026; Ikeda, J. E. (2001). A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nature Genetics, 29(2), 166-173. https://doi.org/10.1038/ng1001-166</Citation></Reference><Reference><Citation>Hadano, S., Kunita, R., Otomo, A., Suzuki-Utsunomiya, K., &amp; Ikeda, J. E. (2007). Molecular and cellular function of ALS2/alsin: Implication of membrane dynamics in neuronal development and degeneration. Neurochemistry International, 51(2-4), 74-84. https://doi.org/10.1016/j.neuint.2007.04.010</Citation></Reference><Reference><Citation>Helal, M., Mazaheri, N., Shalbafan, B., Malamiri, R. A., Dilaver, N., Buchert, R., &#x2026; Maroofian, R. (2018). Clinical presentation and natural history of infantile-onset ascending spastic paralysis from three families with an ALS2 founder variant. Neurological Sciences, 39(11), 1917-1925. https://doi.org/10.1007/s10072-018-3526-8</Citation></Reference><Reference><Citation>Hentati, A., Bejaoui, K., Pericak-Vance, M. A., Hentati, F., Speer, M. C., Hung, W. Y., &#x2026; Siddique, T. (1994). Linkage of recessive familial amyotrophic lateral sclerosis to chromosome 2q33-q35. Nature Genetics, 7(3), 425-428. https://doi.org/10.1038/ng0794-425</Citation></Reference><Reference><Citation>Herzfeld, T., Wolf, N., Winter, P., Hackstein, H., Vater, D., &amp; Muller, U. (2009). Maternal uniparental heterodisomy with partial isodisomy of a chromosome 2 carrying a splice acceptor site mutation (IVS9-2A&gt;T) in ALS2 causes infantile-onset ascending spastic paralysis (IAHSP). Neurogenetics, 10(1), 59-64. https://doi.org/10.1007/s10048-008-0148-y</Citation></Reference><Reference><Citation>Hsu, F., Spannl, S., Ferguson, C., Hyman, A. A., &amp; Parton, R. G. (2018). Rab5 and Alsin regulate stress-activated cytoprotective signaling on mitochondria. Elife, 7, e32282. https://doi.org/10.7554/eLife.32282</Citation></Reference><Reference><Citation>Kenna, K. P., McLaughlin, R. L., Byrne, S., Elamin, M., Heverin, M., Kenny, E. M., &#x2026; Hardiman, O. (2013). Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing. Journal of Medical Genetics, 50(11), 776-783. https://doi.org/10.1136/jmedgenet-2013-101795</Citation></Reference><Reference><Citation>Kim, H. J., Oh, K. W., Kwon, M. J., Oh, S. I., Park, J. S., Kim, Y. E., &#x2026; Kim, S. H. (2016). Identification of mutations in Korean patients with amyotrophic lateral sclerosis using multigene panel testing. Neurobiology of Aging, 37, 209-216. https://doi.org/10.1016/j.neurobiolaging.2015.09.012</Citation></Reference><Reference><Citation>Kress, J. A., Kuhnlein, P., Winter, P., Ludolph, A. C., Kassubek, J., Muller, U., &amp; Sperfeld, A. D. (2005). Novel mutation in the ALS2 gene in juvenile amyotrophic lateral sclerosis. Annals of Neurology, 58(5), 800-803. https://doi.org/10.1002/ana.20665</Citation></Reference><Reference><Citation>Lesca, G., Eymard-Pierre, E., Santorelli, F. M., Cusmai, R., Di Capua, M., Valente, E. M., &#x2026; Bertini, E. (2003). Infantile ascending hereditary spastic paralysis (IAHSP): Clinical features in 11 families. Neurology, 60(4), 674-682.</Citation></Reference><Reference><Citation>Luigetti, M., Lattante, S., Conte, A., Romano, A., Zollino, M., Marangi, G., &amp; Sabatelli, M. (2013). A novel compound heterozygous ALS2 mutation in two Italian siblings with juvenile amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 14(5-6), 470-472. https://doi.org/10.3109/21678421.2012.756036</Citation></Reference><Reference><Citation>Mintchev, N., Zamba-Papanicolaou, E., Kleopa, K. A., &amp; Christodoulou, K. (2009). A novel ALS2 splice-site mutation in a Cypriot juvenile-onset primary lateral sclerosis family. Neurology, 72(1), 28-32. https://doi.org/10.1212/01.wnl.0000338530.77394.60</Citation></Reference><Reference><Citation>Nishiyama, A., Niihori, T., Warita, H., Izumi, R., Akiyama, T., Kato, M., &#x2026; Aoki, M. (2017). Comprehensive targeted next-generation sequencing in Japanese familial amyotrophic lateral sclerosis. Neurobiology of Aging, 53, 194-198. https://doi.org/10.1016/j.neurobiolaging.2017.01.004</Citation></Reference><Reference><Citation>Olmez, A., Uyanik, G., Ozg&#xfc;l, R. K., Gross, C., Cirak, S., Elibol, B., &#x2026; Winkler, J. (2006). Further clinical and genetic characterization of SPG11: Hereditary spastic paraplegia with thin corpus callosum. Neuropediatrics, 37(2), 59-66. https://doi.org/10.1055/s-2006-923982</Citation></Reference><Reference><Citation>Orrell, R. W. (1993). ALS2-related disorders. In R. A. Pagon, M. P. Adam, H. H. Ardinger, S. E. Wallace, A. Amemiya, L. J. H. Bean, et al. (Eds.), GeneReviews(R). Seattle, WA: University of Washington.</Citation></Reference><Reference><Citation>Otomo, A., Hadano, S., Okada, T., Mizumura, H., Kunita, R., Nishijima, H., &#x2026; Ikeda, J. E. (2003). ALS2, a novel guanine nucleotide exchange factor for the small GTPase Rab5, is implicated in endosomal dynamics. Human Molecular Genetics, 12(14), 1671-1687. https://doi.org/10.1093/hmg/ddg184</Citation></Reference><Reference><Citation>Panzeri, C., De Palma, C., Martinuzzi, A., Daga, A., De Polo, G., Bresolin, N., &#x2026; Bassi, M. T. (2006). The first ALS2 missense mutation associated with JPLS reveals new aspects of alsin biological function. Brain, 129(7), 1710-1719. https://doi.org/10.1093/brain/awl104</Citation></Reference><Reference><Citation>Racis, L., Tessa, A., Pugliatti, M., Storti, E., Agnetti, V., &amp; Santorelli, F. M. (2014). Infantile-onset ascending hereditary spastic paralysis: A case report and brief literature review. European Journal of Paediatric Neurology, 18(2), 235-239. https://doi.org/10.1016/j.ejpn.2013.09.009</Citation></Reference><Reference><Citation>Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., &#x2026; Rehm, H. L. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine, 17(5), 405-424. https://doi.org/10.1038/gim.2015.30</Citation></Reference><Reference><Citation>Rozen, S., &amp; Skaletsky, H. (2000). Primer3 on the WWW for general users and for biologist programmers. Methods in Molecular Biology, 132, 365-386.</Citation></Reference><Reference><Citation>Sato, K., Otomo, A., Ueda, M. T., Hiratsuka, Y., Suzuki-Utsunomiya, K., Sugiyama, J., &#x2026; Nakagawa, S. (2018). Altered oligomeric states in pathogenic ALS2 variants associated with juvenile motor neuron diseases cause loss of ALS2-mediated endosomal function. Journal of Biological Chemistry, 293(44), 17135-17153. https://doi.org/10.1074/jbc.RA118.003849</Citation></Reference><Reference><Citation>Sheerin, U. M., Schneider, S. A., Carr, L., Deuschl, G., Hopfner, F., Stamelou, M., &#x2026; Bhatia, K. P. (2014). ALS2 mutations: Juvenile amyotrophic lateral sclerosis and generalized dystonia. Neurology, 82(12), 1065-1067. https://doi.org/10.1212/wnl.0000000000000254</Citation></Reference><Reference><Citation>Shirakawa, K., Suzuki, H., Ito, M., Kono, S., Uchiyama, T., Ohashi, T., &amp; Miyajima, H. (2009). Novel compound heterozygous ALS2 mutations cause juvenile amyotrophic lateral sclerosis in Japan. Neurology, 73(24), 2124-2126. https://doi.org/10.1212/WNL.0b013e3181c67be0</Citation></Reference><Reference><Citation>Siddiqi, S., Foo, J. N., Vu, A., Azim, S., Silver, D. L., Mansoor, A., &#x2026; Khor, C. C. (2014). A novel splice-site mutation in ALS2 establishes the diagnosis of juvenile amyotrophic lateral sclerosis in a family with early onset anarthria and generalized dystonias. PLoS One, 9(12), e113258. https://doi.org/10.1371/journal.pone.0113258</Citation></Reference><Reference><Citation>Soares, D. C., Barlow, P. N., Porteous, D. J., &amp; Devon, R. S. (2009). An interrupted beta-propeller and protein disorder: Structural bioinformatics insights into the N-terminus of alsin. Journal of Molecular Modeling, 15(2), 113-122. https://doi.org/10.1007/s00894-008-0381-1</Citation></Reference><Reference><Citation>Sztriha, L., Panzeri, C., Kalmanchey, R., Szabo, N., Endreffy, E., Turi, S., &#x2026; Bassi, M. T. (2008). First case of compound heterozygosity in ALS2 gene in infantile-onset ascending spastic paralysis with bulbar involvement. Clinical Genetics, 73(6), 591-593. https://doi.org/10.1111/j.1399-0004.2008.00993.x</Citation></Reference><Reference><Citation>Tariq, H., Mukhtar, S., &amp; Naz, S. (2017). A novel mutation in ALS2 associated with severe and progressive infantile onset of spastic paralysis. Journal of Neurogenetics, 31(1-2), 26-29. https://doi.org/10.1080/01677063.2017.1324441</Citation></Reference><Reference><Citation>Verschuuren-Bemelmans, C. C., Winter, P., Sival, D. A., Elting, J. W., Brouwer, O. F., &amp; Muller, U. (2008). Novel homozygous ALS2 nonsense mutation (p.Gln715X) in sibs with infantile-onset ascending spastic paralysis: The first cases from northwestern Europe. European Journal of Human Genetics, 16(11), 1407-1411. https://doi.org/10.1038/ejhg.2008.108</Citation></Reference><Reference><Citation>Wakil, S. M., Ramzan, K., Abuthuraya, R., Hagos, S., Al-Dossari, H., Al-Omar, R., &#x2026; Bohlega, S. (2014). Infantile-onset ascending hereditary spastic paraplegia with bulbar involvement due to the novel ALS2 mutation c.2761C&gt;T. Gene, 536(1), 217-220. https://doi.org/10.1016/j.gene.2013.11.043</Citation></Reference><Reference><Citation>Xie, F., Cen, Z. D., Xiao, J. F., &amp; Luo, W. (2015). Novel compound heterozygous ALS2 mutations in two Chinese siblings with infantile ascending hereditary spastic paralysis. Neurological Sciences, 36(7), 1279-1280. https://doi.org/10.1007/s10072-014-2018-8</Citation></Reference><Reference><Citation>Yang, Y., Hentati, A., Deng, H. X., Dabbagh, O., Sasaki, T., Hirano, M., &#x2026; Siddique, T. (2001). The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nature Genetics, 29(2), 160-165. https://doi.org/10.1038/ng1001-160</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>